+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Antibody Therapeutic Market: Focus on Format, Disease Area, Route of Administration, End Users, Region, and Competitive Landscape - Analysis and Forecast, 2024-2033

  • PDF Icon

    Report

  • 137 Pages
  • December 2023
  • Region: Global
  • BIS Research
  • ID: 5915454
10% Free customization
10% Free customization

This report comes with 10% free customization, enabling you to add data that meets your specific business needs.

The global antibody therapeutic market occupies a pivotal role within the biopharmaceutical and life sciences sectors, dedicated to the manufacturing, advancement, and commercialization of antibodies with diverse applications in medical and research domains. These antibodies, or immunoglobulins, are essential proteins generated by the immune system, crucial for identifying and neutralizing harmful pathogens, toxins, and foreign substances. Within the market context, antibodies are produced, modified, and applied for a spectrum of purposes, encompassing diagnostics, therapeutics, and research endeavors, spanning disease detection and treatment to laboratory experiments and pharmaceutical development.

The expansion of the global antibody therapeutic markets was propelled by several influential factors. Primarily, the rising prevalence of chronic diseases and the escalating demand for targeted therapies have intensified the quest for innovative treatment modalities.

Market Segmentation:

Segmentation 1: by Disease Area

  • Autoimmune and Inflammatory Disease
  • Oncology
  • Haematology
  • Infectious Disease
  • Osteology
  • Immunology
  • Neurology
  • Others Disease Area

Segmentation 2: by Route of Administration

  • Intravenous
  • Subcutaneous
  • Others Route of Administration

Segmentation 3: by End-User

  • Hospitals
  • Long term Care Facilities
  • Others End-User

Segmentation 4: by Format

  • Monoclonal Antibodies
  • Polyclonal Antibodies
  • Antibody Fragments
  • Bispecific Antibodies
  • Others Novel Antibody Therapies

Segmentation 5: by Region

  • North America
  • Europe
  • Asia-Pacific
  • Rest-of-the-World

Key Questions Answered

  • What are the growth opportunities for new entrants in the global antibody therapeutic sector?
  • Who are the primary players operating within the global antibody therapeutics market?
  • What key strategies are likely to be embraced by participants aiming to expand their share in the global antibody therapeutic industry?
  • How is the competitive landscape shaping up in the global antibody therapeutics market?
  • What emerging trends might impact the growth of the global antibody therapeutics market?
  • Which product type segment is anticipated to demonstrate a substantial CAGR in the future?
  • Which application segment is poised to capture a significant share in the global antibody therapeutic industry?
  • Which region presents lucrative opportunities for manufacturers in the global antibody therapeutics market?


This product will be delivered within 3-5 business days.

Table of Contents

1 Markets
1.1 Trends: Current and Future Impact Assessment
1.1.1 Sample Text
1.1.2 Trend 1
1.1.3 Trend 2
1.1.4 Trend 3
1.2 Supply chain Overview
1.2.1 Value Chain Analysis
1.2.2 Market Map
1.3 Research and Development Review
1.3.1 Patent Filing Trend (by Country, Company)
1.4 Regulatory Landscape
1.5 Impact Analysis for Key Global Events - COVID-19
1.6 Market Dynamics Overview
1.6.1 Market Drivers
1.6.2 Market Restraints
1.6.3 Market Opportunities
2 Application
2.1 Application Segmentation
2.2 Application Summary
2.3 Global Antibody Therapeutic Market (By Disease Area)
2.3.1 Autoimmune and Inflammatory Disease
2.3.2 Oncology
2.3.3 Haematology
2.3.4 Infectious Disease
2.3.5 Osteology
2.3.6 Immunology
2.3.7 Neurology
2.3.8 Others Disease Area
2.4 Global Antibody Therapeutic Market (By Route of Administration)
2.4.1 Intravenous
2.4.2 Subcutaneous
2.4.3 Others Route of Administration
2.5 Global Antibody Therapeutic Market (By End-User)
2.5.1 Hospitals
2.5.2 Long term Care Facilities
2.5.3 Others End-User
3 Products
3.1 Product Segmentation
3.2 Product Summary
3.3 Global Antibody Therapeutic Market
3.3.1 Market Overview
3.3.1.1 Analyst View
3.4 Global Antibody Therapeutic Market (By Format)
3.4.1 Monoclonal Antibodies
3.4.2 Polyclonal Antibodies
3.4.3 Antibody Fragments
3.4.4 Bispecific Antibodies
3.4.5 Others Novel Antibody Therapies
4 Regions
4.1 Regional Summary
4.2 Drivers and Restraints
4.3 North America
4.3.1 Regional Overview
4.3.2 Driving Factors for Market Growth
4.3.3 Factors Challenging the Market
4.3.4 Application
4.3.5 Product
4.3.6 U.S.
4.3.7 U.S. Antibody Therapeutic Market by Application
4.3.8 Canada
4.3.9 Canada Antibody Therapeutic Market by Application
4.4 Europe
4.4.1 Regional Overview
4.4.2 Driving Factors for Market Growth
4.4.3 Factors Challenging the Market
4.4.4 Application
4.4.5 Product
4.4.6 Germany
4.4.7 Germany Antibody Therapeutic Market by Application
4.4.8 U.K.
4.4.9 U.K. Antibody Therapeutic Market by Application
4.4.10 France
4.4.11 France Antibody Therapeutic Market by Application
4.4.12 Rest of Europe
4.4.13 Rest of Europe Antibody Therapeutic Market by Application
4.5 Asia Pacific
4.5.1 Regional Overview
4.5.2 Driving Factors for Market Growth
4.5.3 Factors Challenging the Market
4.5.4 Application
4.5.5 Product
4.5.6 China
4.5.7 China Antibody Therapeutic Market by Application
4.5.8 Japan
4.5.9 Japan Antibody Therapeutic Market by Application
4.5.10 India
4.5.11 India Antibody Therapeutic Market by Application
4.5.12 Rest-of-Asia-Pacific
4.5.13 Rest-of-Asia-Pacific Antibody Therapeutic Market by Application
4.6 Rest-of-the-World (RoW)
4.6.1 Regional Overview
4.6.2 Driving Factors for Market Growth
4.6.3 Factors Challenging the Market
4.6.4 Application
4.6.5 Product
4.6.6 Latin America
4.6.7 Latin America Antibody Therapeutic Market by Application
4.6.8 The Middle East and Africa
4.6.9 The Middle East and Africa Antibody Therapeutic Market by Application
5 Markets - Competitive Benchmarking & Company Profiles
5.1 Next Frontiers
5.2 Geographic Assessment
5.2.1 Hoffmann-La Roche Ltd.
5.2.1.1 Overview
5.2.1.2 Top Products / Product Portfolio
5.2.1.3 Top Competitors
5.2.1.4 Target Customers
5.2.1.5 Key Personnel
5.2.1.6 Analyst View
5.2.1.7 Market Share
5.2.2 AbbVie, Inc
5.2.2.1 Overview
5.2.2.2 Top Products / Product Portfolio
5.2.2.3 Top Competitors
5.2.2.4 Target Customers
5.2.2.5 Key Personnel
5.2.2.6 Analyst View
5.2.2.7 Market Share
5.2.3 Amgen Inc.
5.2.3.1 Overview
5.2.3.2 Top Products / Product Portfolio
5.2.3.3 Top Competitors
5.2.3.4 Target Customers
5.2.3.5 Key Personnel
5.2.3.6 Analyst View
5.2.3.7 Market Share
5.2.4 Bristol-Myers Squibb Company
5.2.4.1 Overview
5.2.4.2 Top Products / Product Portfolio
5.2.4.3 Top Competitors
5.2.4.4 Target Customers
5.2.4.5 Key Personnel
5.2.4.6 Analyst View
5.2.4.7 Market Share
5.2.5 Johnson & Johnson Services, Inc.
5.2.5.1 Overview
5.2.5.2 Top Products / Product Portfolio
5.2.5.3 Top Competitors
5.2.5.4 Target Customers
5.2.5.5 Key Personnel
5.2.5.6 Analyst View
5.2.5.7 Market Share
5.2.6 Merck & Co., Inc.
5.2.6.1 Overview
5.2.6.2 Top Products / Product Portfolio
5.2.6.3 Top Competitors
5.2.6.4 Target Customers
5.2.6.5 Key Personnel
5.2.6.6 Analyst View
5.2.6.7 Market Share
5.2.7 Regeneron Pharmaceuticals Inc.
5.2.7.1 Overview
5.2.7.2 Top Products / Product Portfolio
5.2.7.3 Top Competitors
5.2.7.4 Target Customers
5.2.7.5 Key Personnel
5.2.7.6 Analyst View
5.2.7.7 Market Share
5.2.8 Novartis AG
5.2.8.1 Overview
5.2.8.2 Top Products / Product Portfolio
5.2.8.3 Top Competitors
5.2.8.4 Target Customers
5.2.8.5 Key Personnel
5.2.8.6 Analyst View
5.2.8.7 Market Share
5.2.9 AstraZeneca
5.2.9.1 Overview
5.2.9.2 Top Products / Product Portfolio
5.2.9.3 Top Competitors
5.2.9.4 Target Customers
5.2.9.5 Key Personnel
5.2.9.6 Analyst View
5.2.9.7 Market Share
5.2.10 Eli Lilly and Company
5.2.10.1 Overview
5.2.10.2 Top Products / Product Portfolio
5.2.10.3 Top Competitors
5.2.10.4 Target Customers
5.2.10.5 Key Personnel
5.2.10.6 Analyst View
5.2.10.7 Market Share
5.2.11 GlaxoSmithKline PLC
5.2.11.1 Overview
5.2.11.2 Top Products / Product Portfolio
5.2.11.3 Top Competitors
5.2.11.4 Target Customers
5.2.11.5 Key Personnel
5.2.11.6 Analyst View
5.2.11.7 Market Share
5.2.12 Takeda Pharmaceutical Company Ltd.
5.2.12.1 Overview
5.2.12.2 Top Products / Product Portfolio
5.2.12.3 Top Competitors
5.2.12.4 Target Customers
5.2.12.5 Key Personnel
5.2.12.6 Analyst View
5.2.12.7 Market Share
5.2.13 Abcam PLC
5.2.13.1 Overview
5.2.13.2 Top Products / Product Portfolio
5.2.13.3 Top Competitors
5.2.13.4 Target Customers
5.2.13.5 Key Personnel
5.2.13.6 Analyst View
5.2.13.7 Market Share
5.2.14 Thermo Fisher Scientific, Inc
5.2.14.1 Overview
5.2.14.2 Top Products / Product Portfolio
5.2.14.3 Top Competitors
5.2.14.4 Target Customers
5.2.14.5 Key Personnel
5.2.14.6 Analyst View
5.2.14.7 Market Share
5.2.15 Cell Signaling Technology
5.2.15.1 Overview
5.2.15.2 Top Products / Product Portfolio
5.2.15.3 Top Competitors
5.2.15.4 Target Customers
5.2.15.5 Key Personnel
5.2.15.6 Analyst View
5.2.15.7 Market Share
6 Research Methodology
6.1 Data Sources
6.1.1 Primary Data Sources
6.1.2 Secondary Data Sources
6.1.3 Data Triangulation
6.2 Market Estimation and Forecast
List of Figures
Figure 1: Global Antibody Therapeutic Market, by region, 2022, 2026, and 2033
Figure 2: Pricing/Cost Analysis by Region, Supply Chain
Figure 3: Global Antibody Therapeutic Market, by Format, 2022, 2026, and 2033
Figure 4: Global Antibody Therapeutic Market, by Disease Area, 2022, 2026, and 2033
Figure 5: Global Antibody Therapeutic Market, by Route of Administration, 2022, 2026, and 2033
Figure 6: Global Antibody Therapeutic Market, by End User, 2022, 2026, and 2033
Figure 7: Global Antibody Therapeutic Market, Recent Developments
Figure 8: Supply chain and Identifying Risks within the Supply Chain
Figure 9: Global Antibody Therapeutic Market, 2022, 2026, and 2023
Figure 10: Global Antibody Therapeutic Market, 2022, 2026, and 2026
Figure 11: Impact Analysis of Market Navigating Factors
Figure 12: U.S. Antibody Therapeutic Market, By Disease Area ($ Million), 2022,2026, and 2033
Figure 13: U.S. Antibody Therapeutic Market, By End-User ($ Million), 2022, 2026, and 2033
Figure 14: Canada Antibody Therapeutic Market, By Disease Area ($ Million), 2022,2026, and 2033
Figure 15: Canada Antibody Therapeutic Market, By End-User ($ Million), 2022, 2026, and 2033
Figure 16: Germany Antibody Therapeutic Market, By Disease Area ($ Million), 2022,2026, and 2033
Figure 17: Germany Antibody Therapeutic Market, By End-User ($ Million), 2022, 2026, and 2033
Figure 18: U.K. Antibody Therapeutic Market, By Disease Area ($ Million), 2022,2026, and 2033
Figure 19: U.K. Antibody Therapeutic Market, By End-User ($ Million), 2022, 2026, and 2033
Figure 20: France Antibody Therapeutic Market, By Disease Area ($ Million), 2022,2026, and 2033
Figure 21: France Antibody Therapeutic Market, By End-User ($ Million), 2022, 2026, and 2033
Figure 22: Rest of Europe Antibody Therapeutic Market, By Disease Area ($ Million), 2022,2026, and 2033
Figure 23: Rest of Europe Antibody Therapeutic Market, By End-User ($ Million), 2022, 2026, and 2033
Figure 24: China Antibody Therapeutic Market, By Disease Area ($ Million), 2022,2026, and 2033
Figure 25: China Antibody Therapeutic Market, By End-User ($ Million), 2022, 2026, and 2033
Figure 26: Japan Antibody Therapeutic Market, By Disease Area ($ Million), 2022,2026, and 2033
Figure 27: Japan Antibody Therapeutic Market, By End-User ($ Million), 2022, 2026, and 2033
Figure 28: India Antibody Therapeutic Market, By Disease Area ($ Million), 2022,2026, and 2033
Figure 29: India Antibody Therapeutic Market, By End-User ($ Million), 2022, 2026, and 2033
Figure 30: Rest-of-Asia-Pacific Antibody Therapeutic Market, By Disease Area ($ Million), 2022,2026, and 2033
Figure 31: Rest-of-Asia-Pacific Antibody Therapeutic Market, By End-User ($ Million), 2022, 2026, and 2033
Figure 32: Latin America Antibody Therapeutic Market, By Disease Area ($ Million), 2022,2026, and 2033
Figure 33: Latin America Antibody Therapeutic Market, By End-User ($ Million), 2022, 2026, and 2033
Figure 34: The Middle East and Africa Antibody Therapeutic Market, By Disease Area ($ Million), 2022,2026, and 2033
Figure 35: The Middle East and Africa Antibody Therapeutic Market, By End-User ($ Million), 2022, 2026, and 2033
Figure 36: Strategic Initiatives, 2020 - 2023
Figure 37: Share of Strategic Initiatives
Figure 38: Data Triangulation
Figure 39: Top-Down and Bottom-Up Approach
Figure 40: Assumptions and Limitations
List of Tables
Table 1: Market Snapshot
Table 2: Global Antibody Therapeutic Market, Opportunity
Table 3: Global Antibody Therapeutic Market, by Product, $Million, 2022-2033
Table 4: Antibody Therapeutic Market, By Region, ($ Million), 2022-2033
Table 5: North America Antibody Therapeutic Market, By Disease Area ($ Million), 2022-2033
Table 6: North America Antibody Therapeutic Market, By End User ($ Million), 2022-2033
Table 7: North America Antibody Therapeutic Market, By Format ($ Million), 2022-2033
Table 8: U.S. Antibody Therapeutic Market, By Disease Area ($ Million), 2022-2033
Table 9: U.S. Antibody Therapeutic Market, By End User ($ Million), 2022-2033
Table 10: Canada Antibody Therapeutic Market, By Disease Area ($ Million), 2022-2033
Table 11: Canada Antibody Therapeutic Market, By End User ($ Million), 2022-2033
Table 12: Europe Antibody Therapeutic Market, By Disease Area ($ Million), 2022-2033
Table 13: Europe Antibody Therapeutic Market, By End User ($ Million), 2022-2033
Table 14: Europe Antibody Therapeutic Market, By Format ($ Million), 2022-2033
Table 15: Germany Antibody Therapeutic Market, By Disease Area ($ Million), 2022-2033
Table 16: Germany Antibody Therapeutic Market, By End User ($ Million), 2022-2033
Table 17: U.K. Antibody Therapeutic Market, By Disease Area ($ Million), 2022-2033
Table 18: U.K. Antibody Therapeutic Market, By End User ($ Million), 2022-2033
Table 19: France Antibody Therapeutic Market, By Disease Area ($ Million), 2022-2033
Table 20: France Antibody Therapeutic Market, By End User ($ Million), 2022-2033
Table 21: Rest of Europe Antibody Therapeutic Market, By Disease Area ($ Million), 2022-2033
Table 22: Rest of Europe Antibody Therapeutic Market, By End User ($ Million), 2022-2033
Table 23: Asia Pacific Antibody Therapeutic Market, By Disease Area ($ Million), 2022-2033
Table 24: Asia Pacific Antibody Therapeutic Market, By End User ($ Million), 2022-2033
Table 25: Asia Pacific Antibody Therapeutic Market, By Format ($ Million), 2022-2033
Table 26: China Antibody Therapeutic Market, By Disease Area ($ Million), 2022-2033
Table 27: China Antibody Therapeutic Market, By End User ($ Million), 2022-2033
Table 28: Japan Antibody Therapeutic Market, By Disease Area ($ Million), 2022-2033
Table 29: Japan Antibody Therapeutic Market, By End User ($ Million), 2022-2033
Table 30: India Antibody Therapeutic Market, By Disease Area ($ Million), 2022-2033
Table 31: India Antibody Therapeutic Market, By End User ($ Million), 2022-2033
Table 32: India Antibody Therapeutic Market, By Format ($ Million), 2022-2033
Table 33: Rest-of-Asia-Pacific Antibody Therapeutic Market, By Disease Area ($ Million), 2022-2033
Table 34: Rest-of-Asia-Pacific Antibody Therapeutic Market, By End User ($ Million), 2022-2033
Table 35: Rest-of-the-World Antibody Therapeutic Market, By Disease Area ($ Million), 2022-2033
Table 36: Rest-of-the-World Antibody Therapeutic Market, By End User ($ Million), 2022-2033
Table 37: Rest-of-the-World Antibody Therapeutic Market, By Format ($ Million), 2022-2033
Table 38: Latin America Antibody Therapeutic Market, By Disease Area ($ Million), 2022-2033
Table 39: Latin America Antibody Therapeutic Market, By End User ($ Million), 2022-2033
Table 40: The Middle East and Africa Antibody Therapeutic Market, By Disease Area ($ Million), 2022-2033
Table 41: The Middle East and Africa Antibody Therapeutic Market, By End User ($ Million), 2022-2033
Table 42: Market Share

Executive Summary

The global antibody therapeutic market is projected to experience remarkable growth over the coming years.

The escalating prevalence of chronic diseases such as cancer, autoimmune disorders, and infectious diseases has fueled the demand for antibody therapeutics. These treatments, designed to target specific antigens, are proving to be effective in managing and treating a wide range of medical conditions.

Key Highlights of the Report

Market Overview:

  • Analysis of the current market size and growth potential.
  • Identification of key market drivers, challenges, and opportunities.
  • Regional analysis to understand market dynamics across different geographies.

Segmentation and Market Share:

  • Detailed segmentation based on format, route of administration, disease area, and end-user.
  • Insights into the market share of major players and emerging trends.

Competitive Landscape:

  • Profiling of major players in the antibody therapeutic market.
  • Analysis of competitive strategies, partnerships, and mergers and acquisitions.

Forecast and Outlook:

  • Projection of market trends and growth prospects for the next ten years.
  • Insights into potential disruptions and factors influencing market dynamics.

Key Market Players:

  • AbbVie, Inc
  • Amgen Inc.
  • Johnson & Johnson Services, Inc.
  • Eli Lilly and Company
  • Hoffmann-La Roche Ltd.

Key Questions Answered in this Report:

  • What are the growth opportunities for new entrants in the global antibody therapeutic sector?
  • Who are the primary players operating within the global antibody therapeutics market?
  • What key strategies are likely to be embraced by participants aiming to expand their share in the global antibody therapeutic industry?
  • How is the competitive landscape shaping up in the global antibody therapeutics market?
  • What emerging trends might impact the growth of the global antibody therapeutics market?
  • Which product type segment is anticipated to demonstrate a substantial CAGR in the future?
  • Which application segment is poised to capture a significant share in the global antibody therapeutic industry?
  • Which region presents lucrative opportunities for manufacturers in the global antibody therapeutics market?

Companies Mentioned

  • Hoffmann-La Roche Ltd.
  • AbbVie, Inc
  • Amgen Inc.
  • Bristol-Myers Squibb Company
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Regeneron Pharmaceuticals Inc.
  • Novartis AG
  • AstraZeneca
  • Eli Lilly and Company
  • GlaxoSmithKline plc.
  • Takeda Pharmaceutical Company Ltd.
  • Abcam Plc.
  • Thermo Fisher Scientific, Inc
  • Cell Signaling Technology